Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Talal El Zarif,Elio Adib,Jiaming Huang,Taylor Nonato,Mingjia Li,Arjun Mittra,Michael Lorentsen,Christopher Dittus,Nazli Dizman,Adewunmi Falohun,Noha Abdel-Wahab,Adi Diab,Anand Bankapur,Alexandra Reed,Chul Kim,Aakriti Arora,Edward El-Am,Elie Kozaily,Wassim Abdallah,Ahmad Al-Hader,Batool Abu Ghazal,Anwaar Saeed,Claire Drolen,Alexandra Drakaki,Javier Baena,Tarek Haykal,Alessio Cortellini,Alessia Dalla Pria,Evan Hall,Veli Bakalov,Nathan Bahary,Aarthi Rajkumar,Ankit Mangla,Vishal Shah,Parminder Singh,Frank Aboubakar Nana,Nerea Lopetegui-Lia,Danai Dima,Pauline Funchain,Rabia Saleem,Rachel Woodford,Carlo Genova,Giulia Barletta,Sonam Puri,Vaia Florou,Dame Idossa,Maristella Saponara,Paola Queirolo,Giuseppe Lamberti,Alfredo Addeo,Melissa Bersanelli,Dory Freeman,Wanling Xie,Elad Sharon,Ramya Ramaswami,Mark Bower,Brinda Emu,Kathryn Lurain,Abdul Rafeh Naqash,Amin H. Nassar,Bailey G. Fitzgerald,Tarek H. Mouhieddine,Paul G. Rubinstein,Rana R. McKay,Dwight H. Owen,Robert A. Baiocchi,Neil J. Shah,Melissa G. Lechner,Caroline A. Nebhan,Michael A. Morse,David J. Pinato,Ryan W. Dobbs,Georgina V. Long,Alexander M. Menzies,Erin G. Reid,Elizabeth Y. Chiao,Douglas B. Johnson,Thomas U. Marron,Toni K. Choueiri,Lindsey R. Baden,Guru P. Sonpavde
DOI: https://doi.org/10.1200/JCO.22.02459
IF: 45.3
2023-05-18
Journal of Clinical Oncology
Abstract:PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS This retrospective study included PWH treated with anti–PD-1- or anti–PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/μL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS. CONCLUSION Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.
oncology